Outcomes of aflibercept for post-vitrectomy vitreous hemorrhage in patients with proliferative diabetic retinopathy

• Main Authors: O. O. Putienko (Author), D. M. Pogorilyi (Author), V. O. Putienko (Author)
• Format: Book
• Published: Ukrainian Society of Ophthalmologists, 2021-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Background: The incidence of vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy (PDR) has been reported to vary from 21% to 80%. Purpose: To assess the efficacy of gas exchange tamponade (GET) in combination with intravitreal aflibercept for post-vitrectomy vitreous hemorrhage in patients with PDR. Material and Methods: We reviewed the medical records of 47 patients (47 eyes) who developed vitreous hemorrhage after vitrectomy for PDR and received a 20% C3F8 GET in combination with 2.0-mg intravitreal aflibercept (EYLEA®). Results: At 2 months, examination showed "transparent" vitreous cavity in 43 eyes (91.5%), and vitreous hemorrhage was still present in other 4 eyes (8.6%), including a recurrence in 2 eyes (4.3%). At 6 months, examination showed "transparent" vitreous cavity in 46 eyes (97.9%), and only one eye (2.1%) developed a recurrence of vitreous hemorrhage within two months to six months after primary surgery. At the 2 month follow-up, visual acuity was 0.1 to 0.3 in 24 eyes (51%), better than 0.35 in 17 eyes (36.2%), and lower than 0.1 in only 6 eyes (12.8%). At the 6 month follow-up, visual acuity remained similar to that at month 2, but the number of eyes with visual acuity better than 0.35 increased from 17 to 19. Conclusion: A 20% C3F8 GET in combination with intravitreal aflibercept is an effective method of treatment for vitreous hemorrhage after vitrectomy in patients with PDR and may be widely used in practice.

Item Description

10.31288/oftalmolzh202131014
2412-8740